Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2015 | Retinal Disorders

Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients

Authors: Raimo Tuuminen, Jari Haukka, Sirpa Loukovaara

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2015

Abstract

Purpose

In rhegmatogenous retinal detachment (RRD), intravitreal growth factors and cytokines may compromise post-vitrectomy outcomes. Here, we analysed perioperative intravitreal protein levels of potent vasoactive, pro-inflammatory, and extracellular matrix-remodelling factors in RRD eyes of patients treated with statins and evaluated post-vitrectomy outcome in the same study eyes.

Methods

Institutional, retrospective, observational study of 14 patients operated on for RRD while on statins compared to patients without statin medication (n = 82). Vitreous samples were subjected to protein measurements of angiopoietin (ANGPT)-1 and -2, transforming growth factor-β1, and vascular endothelial growth factor (VEGF) by ELISA, and of matrix metalloproteinase (MMP)-2 and -9 by gelatin zymography. A 1-month best-corrected visual acuity (BCVA) gain was modelled by Student’s T-test and multivariate linear regression with concomitant perioperative medication. Cumulative 12-month revitrectomy frequency was modelled by Kaplan-Meier log-rank test.

Results

Intravitreal levels of ANGPT-2 (49.2 ± 33.1 vs. 112.8 ± 134.1 pg/ml, mean ± SD, p < 0.001), VEGF (2.3 ± 2.4 vs. 17.7 ± 57.8 pg/ml, p = 0.021), and MMP-2 (1107.1 ± 884.6 vs 1976.4 ± 970.1 AU/ml, p = 0.005) in RRD eyes of patients treated with statins were lower than in non-statin-treated controls. Patients on statins had better 1-month BCVA improvement than did those not on statins (p = 0.022), with no difference in 1-year re-vitrectomy rates.

Conclusions

Intravitreal levels of ANGPT-2, VEGF, factors involved in vascular permeability and inflammation, and activity of MMP-2, the factor connected with breakdown of basement membrane and fibroproliferation, were lower in RRD eyes of patients with statin treatment. At 1-month, postoperative BCVA gain was improved in statin-treated RRD eyes, suggesting that statin administration may be effective in preventing inflammation-related PVR formation.

Mervin K, Valter K, Maslim J, Lewis G, Fisher S, Stone J (1999) Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation. Am J Ophthalmol 128(2):155–164CrossRefPubMed

Kubay OV, Charteris DG, Newland HS, Raymond GL (2005) Retinal detachment neuropathology and potential strategies for neuroprotection. Surv Ophthalmol 50(5):463–475CrossRefPubMed

Lo AC, Woo TT, Wong RL, Wong D (2011) Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica 226(Suppl 1):10–17CrossRefPubMed

Charteris DG, Sethi CS, Lewis GP, Fisher SK (2002) Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 16(4):369–374CrossRefPubMed

Pastor JC (1998) Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43(1):3–18CrossRefPubMed

Garweg JG, Tappeiner C, Halberstadt M (2013) Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol 58(4):321–329CrossRefPubMed

Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16–34CrossRefPubMed

Symeonidis C, Diza E, Papakonstantinou E, Souliou E, Dimitrakos SA, Karakiulakis G (2007) Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. Retina 27(9):1279–1285CrossRefPubMed

Hoerster R, Hermann MM, Rosentreter A, Muether PS, Kirchhof B, Fauser S (2013) Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol 97(4):450–453CrossRefPubMed

10.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487CrossRefPubMed

11.

Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, Peschos D, Psilas K, Agnantis NJ (2005) Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract 59(10):1157–1161CrossRefPubMed

12.

Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A (2013) Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol 182(5):1659–1670PubMedCentralCrossRefPubMed

13.

Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT (1998) A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 39(8):1524–1529PubMed

14.

Kawahara S, Hata Y, Kita T, Arita R, Miura M, Nakao S, Mochizuki Y, Enaida H, Kagimoto T, Goto Y, Hafezi-Moghadam A, Ishibashi T (2008) Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 57(10):2784–2793PubMedCentralCrossRefPubMed

15.

Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105(45):17504–17509PubMedCentralCrossRefPubMed

16.

El Ghrably I, Powe DG, Orr G, Fischer D, McIntosh R, Dua HS, Tighe PJ (2004) Apoptosis in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 45(5):1473–1479CrossRefPubMed

17.

Chittiboina P, Ganta V, Monceaux CP, Scott LK, Nanda A, Alexander JS (2013) Angiopoietins as promising biomarkers and potential therapeutic targets in brain injury. Pathophysiology 20(1):15–21CrossRefPubMed

18.

Syrjala SO, Tuuminen R, Nykanen AI, Raissadati A, Dashkevich A, Keranen MA, Arnaudova R, Krebs R, Leow CC, Saharinen P, Alitalo K, Lemström KB (2014) Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am J Transplant 14(5):1096–1108CrossRefPubMed

19.

Loukovaara S, Lehti K, Robciuc A, Pessi T, Holopainen JM, Koli K, Immonen I, Keski-Oja J (2014) Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 252(6):881–888CrossRefPubMed

20.

Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47(4):648–657CrossRefPubMed

21.

Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21(11):1712–1719CrossRefPubMed

22.

Tuuminen R, Syrjala S, Krebs R, Keranen MA, Koli K, Abo-Ramadan U, Neuvonen PJ, Tikkanen JM, Nykanen AI, Lemstrom KB (2011) Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation 124(10):1138–1150CrossRefPubMed

23.

Marcus MW, Muskens RP, Ramdas WD, Wolfs RC, De Jong PT, Vingerling JR, Hofman A, Stricker BH, Jansonius NM (2012) Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS One 7(1):e29724PubMedCentralCrossRefPubMed

24.

Lohi J, Lehti K, Westermarck J, Kahari VM, Keski-Oja J (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239(2):239–247CrossRefPubMed

25.

Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M (2006) Visual acuities “hand motion” and “counting fingers” can be quantified with the freiburg visual acuity test. Invest Ophthalmol Vis Sci 47(3):1236–1240CrossRefPubMed

26.

Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat Inflamm 2012:815937CrossRef

27.

Tuuminen R, Sahanne S, Loukovaara S (2014) Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol. doi:10.1111/aos./2363

28.

Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, El-Remessy AB, Caldwell RW, Marcus DM, Caldwell RB (2009) HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50(10):4934–4940PubMedCentralCrossRefPubMed

29.

Hammes HP, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U (2004) Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53(4):1104–1110CrossRefPubMed

30.

Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552–558CrossRefPubMed

31.

Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96(5A):11F–23FCrossRefPubMed

32.

Ko ML, Chen CF, Peng PH, Peng YH (2011) Simvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina. Exp Eye Res 93(5):580–585CrossRefPubMed

33.

Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118PubMedCentralCrossRefPubMed

34.

Yueyi C, Xiaoguang H, Jingying W, Quansheng S, Jie T, Xin F, Yingsheng X, Chunli S (2013) Calvarial defect healing by recruitment of autogenous osteogenic stem cells using locally applied simvastatin. Biomaterials 34(37):9373–9380CrossRefPubMed

Title: Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients
Authors: Raimo Tuuminen
Jari Haukka
Sirpa Loukovaara
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2015
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-014-2873-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Comparison of epitheliotrophic factors in autologous serum eyedrops from sera of chronic renal failure patients vs. normal controls

Spatial and temporal analyses of posture in strabismic children

Accurate evaluation of relationships among serum lipoprotein lipase mass, visceral fat and retinal nerve fiber layer thickness

Staging of development in Terrien’s degeneration based on corneal curvatures detected by optical coherence tomography

Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection

Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis